{
    "ticker": "LPCN",
    "name": "Lipocine Inc.",
    "description": "Lipocine Inc. is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in Salt Lake City, Utah, Lipocine is leveraging its proprietary drug delivery technology, which allows for the oral delivery of large molecules, to create products aimed at improving patient compliance and outcomes. The company's lead product candidate, LPCN 1021, is a testosterone replacement therapy designed to provide a more convenient and effective treatment option for men with hypogonadism. In addition to LPCN 1021, Lipocine is developing other therapeutic candidates, including LPCN 1144, aimed at treating non-alcoholic steatohepatitis (NASH). Lipocine's commitment to advancing healthcare through its innovative solutions positions it as a key player in the pharmaceutical industry, addressing significant unmet medical needs. By focusing on patient-centric development and leveraging its cutting-edge technology, Lipocine aims to enhance the quality of life for patients suffering from metabolic and endocrine disorders.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Salt Lake City, Utah, USA",
    "founded": "2012",
    "website": "https://www.lipocine.com",
    "ceo": "Dr. Mahesh Patel",
    "social_media": {
        "twitter": "https://twitter.com/lipocine",
        "linkedin": "https://www.linkedin.com/company/lipocine-inc-"
    },
    "investor_relations": "https://www.lipocine.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Mahesh Patel",
            "position": "CEO"
        },
        {
            "name": "R. Scott Bader",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "LPCN 1021",
                "LPCN 1144"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lipocine Inc. | Innovative Biopharmaceuticals",
        "meta_description": "Explore Lipocine Inc., a biopharmaceutical company dedicated to developing innovative therapies for metabolic and endocrine disorders.",
        "keywords": [
            "Lipocine",
            "Biopharmaceuticals",
            "Testosterone Therapy",
            "Metabolic Disorders",
            "Endocrine Disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Lipocine known for?",
            "answer": "Lipocine is known for developing innovative therapies, particularly in testosterone replacement and treatments for metabolic disorders."
        },
        {
            "question": "Who is the CEO of Lipocine?",
            "answer": "Dr. Mahesh Patel is the CEO of Lipocine Inc."
        },
        {
            "question": "Where is Lipocine headquartered?",
            "answer": "Lipocine is headquartered in Salt Lake City, Utah, USA."
        },
        {
            "question": "What are Lipocine's main products?",
            "answer": "Lipocine's main products include LPCN 1021 and LPCN 1144, targeting testosterone replacement and NASH."
        },
        {
            "question": "When was Lipocine founded?",
            "answer": "Lipocine was founded in 2012."
        }
    ],
    "competitors": [
        "AMRN",
        "IBIO",
        "VTVT",
        "HGEN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}